Trinity Delta

RSS Feed

We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.

The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.

We also firmly believe that by putting our clients first, we create long term value for all stakeholders.

Regulatory Information

  • Regulatory Status: Appointed representative
  • ID Number: 725161

Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
AVCT AVACTA GROUP

Avacta: AVA6103 (FAP-Exd) starts Phase Ia FOCUS clinical trial

Avacta has treated its first patient in the first clinical trial of FAP-Exd (AVA6103), a second-generation pre|CISION-enabled peptide-drug conjugate (PDC). FAP-Exd is a novel sustained release PDC with an exatecan payload intended to address the known limitations of the potent Topo I inhibitors (short half-life, severe systemic toxicities). The FOCUS study is designed to generate robust data in four specifically selected solid tumours (cervical, gastric, pancreatic, and small cell lung cancer). ...

04/08/26 April 8, 2026 1 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
AVCT AVACTA GROUP

Trinity Delta Lighthouse: Avacta

Trinity Delta view: Avacta’s successful £10m placing removes funding uncertainty, providing additional working capital and allowing management to retain ownership of its proprietary pre|CISION technology and PDC assets as it advances these towards important catalysts and potentially more lucrative deals. Multiple clinical catalysts are expected which should provide near- and mid-term value inflection points, including progress with faridoxorubicin partnering and, more importantly in our view, fi...

03/27/26 March 27, 2026 1 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
HCM Hutchison China...

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: HUTCHMED’s sustainable profitability aim is underpinned by continued commercial and R&D execution. Geographic expansion ex-China, new indications for current China products, and potential new product approvals will support near-term growth, while M&A and/or in-licensing have a role in the mid-term. Accelerated investment in the highly attractive ATTC platform, which could address a wide range of oncology indications with sizeable market potential, should drive longer-term pro...

HCM HUTCHISON CHINA MEDITECH LTD SPONSORED ADR
03/06/26 March 6, 2026 1 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
AVCT AVACTA GROUP

Trinity Delta Lighthouse: Avacta

Trinity Delta view: Lead compound, faridoxorubicin, has provided proof-of-concept for Avacta’s pre|CISION PDC platform and specifically FAP-activation at the tumour site; however, in our view, greater value lies in next-generation programmes, including AVA6103. AVA6103 is on the cusp of entering the clinic: Phase Ia is due to start in Q126 in four cancer indications (cervical, gastric, pancreatic, small cell lung cancer) identified in conjunction with Tempus AI. This partnership, as well as the ...

02/24/26 February 24, 2026 1 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
SCLP Scancell Holdin...

Trinity Delta Lighthouse: Scancell

Trinity Delta view: Scancell’s H126 results and recent data read outs showcase the progress achieved. The quality and duration of responses seen in the SCOPE study provide reassurance that iSCIB1+ could shift the standard of care in advanced melanoma if replicated in the registrational trial. Inevitably investor attention is now focused on the likely funding mechanism for the trial, with partnership expected to be one of the principal avenues under consideration. However, we would argue the stre...

SCLP SCANCELL HOLDINGS
01/29/26 January 29, 2026 1 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
SAN SANOFI
REDX REDX PHARMA

Trinity Delta Lighthouse: Redx Pharma

Trinity Delta view: he importance of the ROCK pathways has been known for some time, but the chemistry is complex and historically identifying safe and effective selective inhibitors has proved challenging. Redx Phama has a proven medicinal chemistry expertise and has generated what, in our view, is a possible “best-in-class” small molecule. RXC007 is one of two in-house assets (the other is RXC004, a porcupine inhibitor in Phase II trials) and two partnered programmes (with AstraZeneca and Jazz...

SAN SANOFI
REDX REDX PHARMA
09/08/21 September 8, 2021 2 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
HCM Hutchison China...

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: The timing of the fund raise follows hot on the heels of data presented at the ASCO 2021 conference and updates at a recent investor event on several new late-stage programmes to be initiated which highlighted the strength and depth of HUTCHMED’s late-stage pipeline. The in-house discovery platform has generated 10 tyrosine kinase inhibitors that have progressed into the clinic: both as monotherapy and, importantly, in combinations, in China and globally. The first product wa...

HCM HUTCHISON CHINA MEDITECH LIMITED
06/21/21 June 21, 2021 2 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
FUM Futura Medical ...

Trinity Delta Lighthouse: Futura Medical

Trinity Delta view: Although MED3000’s imminent approval in Europe was flagged in March, the receipt of the official documentation paves the way for commercialisation discussions for a number of geographies to proceed at pace. The timings remain uncertain, but we would expect to see a number of deals in place within the next six months. For these geographies, the key sensitivity shifts from regulatory risk to execution risk, particularly the nature and scope of the commercialisation agreements. ...

FUM FUTURA MEDICAL PLC
04/30/21 April 30, 2021 2 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
NXTMS NEXSTIM LTD

Trinity Delta Lighthouse: Nexstim

Trinity Delta view: The oversubscribed rights issue is tangible evidence of support for management’s growth strategy. Demonstrating the value of NBT in accelerated iTBS protocols for severe depression is a key component of the 2020-24 strategic plan. The new funds will also support other plans for NBT and NBS growth and enable achievement of several near and mid-term goals. Updating our Nexstim rNPV model for the raise results in a valuation of €50.6m (€0.08 per share) against our prior €44.2m (...

04/08/21 April 8, 2021 2 EN
Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek
AGY Allergy Therape...

Trinity Delta Lighthouse: Allergy Therapeutics

Trinity Delta view: The start of the biomarker study of Allergy Therapeutics’ peanut allergy vaccine candidate represents a step forward for this development programme and should facilitate a smooth transition into Phase I later this year. It is the first VLP-based vaccine in Allergy’s portfolio and addresses a sizeable and underserved market. The collaboration with Imperial College is significant as both the peanut allergy biomarker study and the wider collaboration should generate important ne...

AGY ALLERGY THERAPEUTICS PLC
01/05/21 January 5, 2021 2 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch